ORIC Pharmaceuticals Receives $53 Million to Develop Prostate Cancer Drug Candidate

ORIC Pharmaceuticals Receives $53 Million to Develop Prostate Cancer Drug Candidate
ORIC Pharmaceuticals issued a press release announcing a B Series financing of $53 million to support the development of the company’s initial drug candidate's first clinical trial and to further develop additional therapies in the company’s pipeline. ORIC’s first drug candidate will focus on the glucocorticoid receptor (GR) as a target for androgen receptor (AR) resistance in prostate cancer, as studies have shown that the GR may substitute AR in driving prostate cancer growth and metastasis in a context of androgen deprivation. ORIC Pharmaceuticals, a company headquartered in San Francisco, California, is a privately-held cancer therapy enterprise driven by the discovery and development of small-molecule drugs that target treatment-resistant cancers, focusing first on advanced prostate cancer. The company was founded in 2014 and is funded by leading biotechnology investors like The Column GroupTopspin PartnersOrbiMed AdvisorsEcoR1 CapitalForesite Capital and Kravis Investment Partners. "We are pleased to have the support of such a distinguished group of biotechnology investors, who share our excitement about the opportunity to solve the pervasive problem of cancer-treatment resistance," claimed Richard Heyman, Ph.D., interim CEO and board memb
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *